News

Genoskin featured in a Business Insider article The press is talking about Genoskin! Amid COVID-19 breakout, Genoskin got attention from Business Insider 's reporter Mia Jankowicz.  We recently communicated on our continued efforts during the pandemic and our preferred access program for research on COVID-19. Genoskin's projects and technology caught the eye of Mia Jankowicz. Mia, a journalist specializing inRead more

Genoskin selected for Round 2 of Mass Challenge Switzerland 2020! A few weeks ago, Genoskin entered the 2020 Mass Challenge Switzerland. We are now excited to announce that our company is moving on to Round 2 judging! Genoskin has been invited to participate in Round 2 judging of the Mass Challenge Switzerland on May 14th. Our Chief Commercial Officer, EricRead more

Genoskin takes part in COVID-19 Virtual Partnering Until May 6th, Genoskin's CCO, Eric Merle, is available for meetings on the COVID-19 Virtual Partnering platform organized by Lyonbiopole, Evaluate Ltd., and Inova. The COVID-19 Virtual Partnering is a one-to-one partnering event created to support the fight against COVID-19 and to accelerate global collaboration. The event is an excellent opportunity to findRead more

COVID-19 update: Genoskin R&D capabilities expanded As the COVID-19 outbreak continues to evolve, our priorities remain safety and contingency in supporting research and first responders. Globally, hospitals are now focused on life-saving efforts. All non-urgent surgeries have therefore been postponed to help hospitals deal with the increasingly high demand of ventilators. These new measures have impacted our sourcing network inRead more

COVID-19 update: Genoskin to maintain US production activity during pandemic. In light of the latest updates on the COVID-19 pandemic, Genoskin’s top priority remains both employees and collaborators’ safety. Thanks to the ability to rely on skin expertise and model production in the US location (Salem, MA), Genoskin continues to provide partners with the available support needed in reliably and quickly

Read more

Genoskin COVID-19 research preferred access program On Friday, March 13th 2020, Genoskin launched a preferred access program for all research teams actively developing therapeutic and vaccine technologies for the COVID-19 pandemic. The World Health Organization (WHO) officially declared on March 11th, the outbreak of COVID-19 a pandemic. The disease caused by SARS-CoV-2 has spread globally. Over 130,000 individuals are affected so

Read more